<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447120</url>
  </required_header>
  <id_info>
    <org_study_id>Maestro_NDB_II</org_study_id>
    <nct_id>NCT02447120</nct_id>
  </id_info>
  <brief_title>Topcon 3D OCT-1 Maestro Reference Database Study II</brief_title>
  <official_title>Topcon 3D OCT-1 Maestro Reference Database Study II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect OCT measurement data on normal healthy eyes in
      order to determine the reference limits for Topcon 3D OCT-1 Maestro based on the percentile
      points for 1%, 5%, 95%, and 99%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to collect OCT measurement data on normal healthy eyes in
      order to determine the reference limits for Topcon 3D OCT-1 Maestro based on the percentile
      points for 1%, 5%, 95%, and 99%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>1 minute</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">504</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Normal Eyes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with no known ocular diseases will be scanned with the Maestro device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D OCT-1 Maestro</intervention_name>
    <description>OCT machines used for diagnostic purposes</description>
    <arm_group_label>Normal Eyes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes (eyes without pathology)

          4. lOP &lt;= 21 mmHg bilaterally

          5. BCVA 20/40 or better (each eye)

          6. Both eyes must be free of eye disease

        Exclusion Criteria for Normal Group

          1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study

          2. Subjects unable to tolerate ophthalmic imaging

          3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses &gt; 20% or false positives&gt;
             33%, or false negatives&gt; 33%

          5. Visual field defects consistent with glaucomatous optic nerve damage based on with at
             least one of the following two findings:

               -  On pattern deviation (PD), there exists a cluster of 3 or more points in an
                  expected location of the visual field depressed below the 5% level, at least 1 of
                  which is depressed below the 1% level;

               -  Glaucoma hemi-field test &quot;outside normal limits.&quot;

          6. Presence of any ocular pathology except for cataract

          7. Narrow angle

          8. History of leukemia, dementia or multiple sclerosis

          9. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Reisman, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB School of Optometry</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California College of Optometry</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Eyecare Center</name>
      <address>
        <city>Livermore</city>
        <state>California</state>
        <zip>94550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western University of Health Sciences</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois College of Optometry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York VA</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY College of Optometry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteers with Healthy Eyes</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

